1. von Figura, K., Gieselmann, V. & Jaeken, J. Metachromatic leukodystrophy. The Metabolic and Molecular Bases of Inherited Disease. 3695–3724 (McGraw-Hill, 2001).
2. Gieselmann, V. Metachromatic leukodystrophy: recent research developments. J Child Neurol 18, 591-594, doi:10.1177/08830738030180090301 (2003).
3. Parikh, S. et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab 114, 501-515, doi:10.1016/j.ymgme.2014.12.434 (2015).
4. Sevin, C., Aubourg, P. & Cartier, N. Enzyme, cell and gene-based therapies for metachromatic leukodystrophy. J. Inherit. Metab. Dis. 30, 175-183, doi:10.1007/s10545-007-0540-z (2007).
5. Groeschel, S. et al. Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. J Inherit Metab Dis 34, 1095-1102, doi:10.1007/s10545-011-9361-1 (2011).
6. Gieselmann, V. & Krageloh-Mann, I. Metachromatic leukodystrophy--an update. Neuropediatrics 41, 1-6, doi:10.1055/s-0030-1253412 (2010).
7. Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R. G. & Sondhi, D. Gene therapy for metachromatic leukodystrophy. J. Neurosci. Res. 94, 1169-1179, doi:10.1002/jnr.23792 (2016).
8. Abbott, N. J. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 36, 437-449, doi:10.1007/s10545-013-9608-0 (2013).
9. Muldoon, L. L. et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab 33, 13-21, doi:10.1038/jcbfm.2012.153 (2013).
10. Kurai, T. et al. AAV1 mediated co-expression of formylglycine-generating enzyme and arylsulfatase a efficiently corrects sulfatide storage in a mouse model of metachromatic leukodystrophy. Mol. Ther. 15, 38-43, doi:10.1038/sj.mt.6300012 (2007).
11. Piguet, F. et al. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum. Gene Ther. 23, 903-914, doi:10.1089/hum.2012.015 (2012).
12. Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158, doi:10.1126/science.1233158 (2013).
13. Sessa, M. et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. The Lancet 388, 476-487, doi:10.1016/s0140-6736(16)30374-9 (2016).
14. Miyake, N., Miyake, K., Asakawa, N., Yamamoto, M. & Shimada, T. Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector. Gene Ther 21, 427-433, doi:10.1038/gt.2014.17 (2014).
15. Iwamoto, N. et al. Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. J Gene Med 11, 498-505, doi:10.1002/jgm.1325 (2009).
16. Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J. & Jude Samulski, R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20, 450-459, doi:10.1038/gt.2012.101 (2013).
17. Hirai, T. et al. Intrathecal shRNA-AAV9 inhibits target protein expression in the spinal cord and dorsal root ganglia of adult mice. Hum Gene Ther Methods 23, 119-127, doi:10.1089/hgtb.2012.035 (2012).
18. Snyder, B. R. et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum. Gene Ther. 22, 1129-1135, doi:10.1089/hum.2011.008 (2011).
19. Hordeaux, J. et al. Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathol Commun 5, 66, doi:10.1186/s40478-017-0464-2 (2017).
20. Storek, B. et al. Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol. Pain 2, 4, doi:10.1186/1744-8069-2-4 (2006).
21. Hinderer, C. et al. Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev 1, 14051, doi:10.1038/mtm.2014.51 (2014).
22. Bailey, R. M., Rozenberg, A. & Gray, S. J. Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies. Brain Res. 1739, 146832, doi:10.1016/j.brainres.2020.146832 (2020).
23. Bey, K. et al. Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. Gene Ther. 24, 325-332, doi:10.1038/gt.2017.18 (2017).
24. Miyake, N., Miyake, K., Karlsson, S. & Shimada, T. Successful treatment of metachromatic leukodystrophy using bone marrow transplantation of HoxB4 overexpressing cells. Mol Ther 18, 1373-1378, doi:10.1038/mt.2010.74 (2010).
25. Miyake, N., Miyake, K., Yamamoto, M., Hirai, Y. & Shimada, T. Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors. Brain Res 1389, 19-26, doi:10.1016/j.brainres.2011.03.014 (2011).
26. Byrne, B. J., Falk, D. J., Clement, N. & Mah, C. S. Gene therapy approaches for lysosomal storage disease: next-generation treatment. Hum. Gene Ther. 23, 808-815, doi:10.1089/hum.2012.140 (2012).
27. Schuster, D. J. et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front. Neuroanat. 8, 42, doi:10.3389/fnana.2014.00042 (2014).
28. Meyer, K. et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol. Ther. 23, 477-487, doi:10.1038/mt.2014.210 (2015).
29. Sevin, C. et al. Intracerebral gene therapy in children with metachromatic leukodystrophy: Results of a phase I/II trial. Mol. Genet. Metab. 123, S129, doi:doi: 10.1016/j.ymgme.2017.12.352 (2018).
30. Fu, H. et al. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther. 14, 1065-1077, doi:10.1038/sj.gt.3302961 (2007).
31. Gurda, B. L. et al. Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Mol. Ther. 24, 206-216, doi:10.1038/mt.2015.189 (2016).
32. Hess, B. et al. Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc Natl Acad Sci U S A 93, 14821-14826 (1996).
33. D'Hooge, R., Coenen, R., Gieselmann, V., Lullmann-Rauch, R. & De Deyn, P. P. Decline in brainstem auditory-evoked potentials coincides with loss of spiral ganglion cells in arylsulfatase A-deficient mice. Brain Res 847, 352-356 (1999).
34. Wittke, D., Hartmann, D., Gieselmann, V. & Lullmann-Rauch, R. Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution. Acta Neuropathol. 108, 261-271, doi:10.1007/s00401-004-0883-6 (2004).
35. Noro, T. et al. Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer Res 64, 7486-7490, doi:10.1158/0008-5472.CAN-03-1296 (2004).
36. Gao, G. P. et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99, 11854-11859, doi:10.1073/pnas.182412299 (2002).
37. Miyake, K., Miyake, N., Yamazaki, Y., Shimada, T. & Hirai, Y. Serotype-independent method of recombinant adeno-associated virus (AAV) vector production and purification. J Nippon Med Sch 79, 394-402 (2012).
38. Fu, H. et al. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 8, 911-917 (2003).
39. Yamazaki, Y., Hirai, Y., Miyake, K. & Shimada, T. Targeted gene transfer into ependymal cells through intraventricular injection of AAV1 vector and long-term enzyme replacement via the CSF. Scientific reports 4, 5506, doi:10.1038/srep05506 (2014).
40. Scott, J. E. & Dorling, J. Differential staining of acid glycosaminoglycans (mucopolysaccharides) by alcian blue in salt solutions. Histochemie 5, 221-233 (1965).
41. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497-509 (1957).
42. Carter, R. J. et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19, 3248-3257 (1999).